Alere Company Profile (NYSE:ALR)

About Alere (NYSE:ALR)

Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:ALR
  • CUSIP: 01449J10
  • Web: www.alere.com
Capitalization:
  • Market Cap: $4.25 billion
  • Outstanding Shares: 86,955,000
Average Prices:
  • 50 Day Moving Avg: $47.66
  • 200 Day Moving Avg: $41.11
  • 52 Week Range: $31.47 - $49.53
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 22.92
  • P/E Growth: 2.34
Sales & Book Value:
  • Annual Revenue: $2.38 billion
  • Price / Sales: 1.78
  • Book Value: $21.03 per share
  • Price / Book: 2.32
Profitability:
  • EBIDTA: $419.99 million
  • Net Margins: -1.64%
  • Return on Equity: 8.01%
  • Return on Assets: 1.97%
Debt:
  • Debt-to-Equity Ratio: 2.02%
  • Current Ratio: 2.14%
  • Quick Ratio: 1.65%
Misc:
  • Average Volume: 1.70 million shs.
  • Beta: 0.6
  • Short Ratio: 3.19
 

Frequently Asked Questions for Alere (NYSE:ALR)

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc (NYSE:ALR) issued its quarterly earnings results on Friday, November, 4th. The company reported $0.19 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.54 by $0.35. The firm earned $582 million during the quarter, compared to the consensus estimate of $605.50 million. Alere had a negative net margin of 1.64% and a positive return on equity of 8.01%. Alere's revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.10) earnings per share. View Alere's Earnings History.

Where is Alere's stock going? Where will Alere's stock price be in 2017?

6 brokers have issued 12 month target prices for Alere's stock. Their forecasts range from $42.00 to $56.00. On average, they expect Alere's share price to reach $49.60 in the next year. View Analyst Ratings for Alere.

What are analysts saying about Alere stock?

Here are some recent quotes from research analysts about Alere stock:

  • 1. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)
  • 2. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (4/19/2017)

Are investors shorting Alere?

Alere saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,289,823 shares, a decrease of 31.0% from the April 28th total of 1,869,308 shares. Based on an average trading volume of 2,382,140 shares, the short-interest ratio is currently 0.5 days. Approximately 1.5% of the shares of the company are short sold.

Who are some of Alere's key competitors?

Who are Alere's key executives?

Alere's management team includes the folowing people:

  • Gregg J. Powers, Independent Chairman of the Board
  • Namal Nawana, President, Chief Executive Officer, Director
  • James F. Hinrichs, Chief Financial Officer, Executive Vice President
  • Daniella Cramp, Global President - Cardiometabolic Business Unit
  • Sanjay Malkani, Global President - Toxicology
  • Avi Pelossof, Global President - Infectious Disease Business Unit
  • Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Secretary
  • John Bridgen Ph.D., Senior Vice President - Business Development
  • Mark Gladwell, Senior Vice President - Global Operations
  • Melissa Guerdan, Senior Vice President - Global Quality and Regulatory Assurance

Who owns Alere stock?

Alere's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Iridian Asset Management LLC CT (0.00%), Dimensional Fund Advisors LP (0.00%), Diamond Hill Capital Management Inc. (2.79%), USS Investment Management Ltd (0.00%) and First Eagle Investment Management LLC (1.58%). Company insiders that own Alere stock include James F Hinrichs, John Bridgen, Mark Gladwell, Melissa Guerdan, Robert Bernard Hargadon and Sanjay Malkani. View Institutional Ownership Trends for Alere.

Who sold Alere stock? Who is selling Alere stock?

Alere's stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, First Eagle Investment Management LLC, Cowen Group Inc., Jennison Associates LLC, York Capital Management Global Advisors LLC, Gabelli Funds LLC, Stonepine Capital Management LLC and Everett Capital Advisors UK LLP. View Insider Buying and Selling for Alere.

Who bought Alere stock? Who is buying Alere stock?

Alere's stock was purchased by a variety of institutional investors in the last quarter, including Litespeed Management L.L.C., Renaissance Technologies LLC, Vanguard Group Inc., Laurion Capital Management LP, First Trust Advisors LP, Janus Capital Management LLC, Cornerstone Capital Management Holdings LLC. and Jane Street Group LLC. Company insiders that have bought Alere stock in the last two years include James F Hinrichs and Robert Bernard Hargadon. View Insider Buying and Selling for Alere.

How do I buy Alere stock?

Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alere's stock price today?

One share of Alere stock can currently be purchased for approximately $48.82.


MarketBeat Community Rating for Alere (NYSE ALR)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alere (NYSE:ALR) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $49.60 (1.60% upside)

Analysts' Ratings History for Alere (NYSE:ALR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/22/2017Canaccord GenuityReiterated RatingBuy$51.00LowView Rating Details
5/15/2017Craig HallumDowngradeBuy -> HoldLowView Rating Details
4/17/2017Jefferies Group LLCLower Price TargetHold$56.00 -> $51.00HighView Rating Details
11/4/2016Goldman Sachs Group IncLower Price TargetNeutral$45.00 -> $42.00N/AView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$56.00N/AView Rating Details
2/2/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/5/2015WedbushLower Price TargetNeutral$43.00 -> $39.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Alere (NYSE:ALR)
Earnings by Quarter for Alere (NYSE:ALR)
Earnings History by Quarter for Alere (NYSE:ALR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 16$0.54$0.19$605.50 million$582.00 millionViewN/AView Earnings Details
9/6/2016Q216$0.58($0.46)$621.95 million$611.10 millionViewN/AView Earnings Details
8/17/2016Q116$0.56($0.18)$578.00 millionViewN/AView Earnings Details
8/8/2016Q415$0.58($0.28)$662.04 million$623.00 millionViewN/AView Earnings Details
11/4/2015Q315$0.55$0.49$646.29 million$602.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.49$625.67 million$629.00 millionViewN/AView Earnings Details
5/5/2015Q115$0.49$0.57$612.93 million$610.40 millionViewN/AView Earnings Details
2/10/2015Q414$0.63$0.61$698.56 million$666.90 millionViewN/AView Earnings Details
10/28/2014Q314$0.52$0.48$743.30 million$736.20 millionViewN/AView Earnings Details
8/4/2014Q214$0.58$0.43$747.55 million$738.30 millionViewN/AView Earnings Details
4/29/2014Q114$0.55$0.55$738.70 million$716.60 millionViewN/AView Earnings Details
2/6/2014Q413$0.56$0.62$770.70 million$772.30 millionViewN/AView Earnings Details
10/29/2013Q313$0.53$0.59$737.66 million$753.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.48$0.64$720.24 million$764.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.51$0.53$727.66 million$739.20 millionViewN/AView Earnings Details
2/15/2013Q4 2012$0.57$0.55$714.75 million$755.80 millionViewN/AView Earnings Details
11/8/2012Q312$0.53$0.43$690.76 million$691.40 millionViewN/AView Earnings Details
8/8/2012$0.53($0.23)ViewN/AView Earnings Details
4/30/2012$0.67$0.77ViewN/AView Earnings Details
2/8/2012$0.71$0.74ViewN/AView Earnings Details
10/26/2011$0.57$0.67ViewN/AView Earnings Details
7/27/2011$0.58$0.46ViewN/AView Earnings Details
4/27/2011$0.61$0.61ViewN/AView Earnings Details
2/17/2011$0.66$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alere (NYSE:ALR)
Current Year EPS Consensus Estimate: $2.09 EPS
Next Year EPS Consensus Estimate: $2.13 EPS

Dividends

Dividend History for Alere (NYSE:ALR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alere (NYSE:ALR)
Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 91.82%
Insider Trades by Quarter for Alere (NYSE:ALR)
Institutional Ownership by Quarter for Alere (NYSE:ALR)
Insider Trades by Quarter for Alere (NYSE:ALR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016Melissa GuerdanSVPSell2,500$54.00$135,000.00View SEC Filing  
11/13/2015Robert Bernard HargadonSVPBuy1,000$38.99$38,990.00View SEC Filing  
11/12/2015James F HinrichsCFOBuy10,000$39.97$399,700.00View SEC Filing  
9/3/2015Mark GladwellVPSell2,651$52.27$138,567.77View SEC Filing  
9/3/2015Melissa GuerdanSVPSell5,135$52.00$267,020.00View SEC Filing  
9/1/2015Melissa GuerdanSVPSell5,000$50.48$252,400.00View SEC Filing  
8/31/2015Mark GladwellVPSell27,513$52.23$1,437,003.99View SEC Filing  
8/14/2015Sanjay MalkaniInsiderSell31,460$54.60$1,717,716.00View SEC Filing  
6/8/2015Sanjay MalkaniInsiderSell24,331$50.87$1,237,717.97View SEC Filing  
6/4/2015Sanjay MalkaniInsiderSell15,669$52.18$817,608.42View SEC Filing  
6/1/2015John BridgenSVPSell7,500$51.19$383,925.00View SEC Filing  
4/6/2015Melissa GuerdanSVPSell2,500$50.00$125,000.00View SEC Filing  
3/23/2015Melissa GuerdanSVPSell13,476$48.35$651,564.60View SEC Filing  
3/17/2015John BridgenSVPSell25,000$48.53$1,213,250.00View SEC Filing  
3/16/2015Carla FlakneCAOSell8,500$48.99$416,415.00View SEC Filing  
1/16/2015Carla FlakneCAOSell10,000$42.45$424,500.00View SEC Filing  
12/24/2014Don DudekDirectorBuy40,000$0.01$500.00
12/11/2014John BridgenSVPSell50,000$37.07$1,853,500.00View SEC Filing  
8/15/2014Dave TeitelCFOSell10,000$35.07$350,700.00View SEC Filing  
8/15/2013Dave TeitelCFOSell10,000$31.73$317,300.00View SEC Filing  
8/5/2013Michael Lester CottonInsiderSell12,500$33.82$422,750.00View SEC Filing  
5/31/2013Michael Lester CottonInsiderSell8,750$25.86$226,275.00View SEC Filing  
3/5/2013John QuelchDirectorSell20,220$23.49$474,967.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alere (NYSE:ALR)
Latest Headlines for Alere (NYSE:ALR)
Source:
DateHeadline
americanbankingnews.com logoAlere's (ALR) Hold Rating Reiterated at BTIG Research
www.americanbankingnews.com - May 24 at 3:56 PM
nasdaq.com logoAlere Sees Wider Loss From Cont. Ops, Lower Revenue In Q4 - Quick Facts
www.nasdaq.com - May 24 at 3:28 PM
streetinsider.com logoAlere (ALR) Offers Prelim. Q1 Results and Update on Form 10-K
www.streetinsider.com - May 24 at 3:28 PM
americanbankingnews.com logoAlere's (ALR) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - May 22 at 4:28 PM
streetinsider.com logoAlere (ALR) Offers Prelim. Q1 Results and Update on Form 10-K - StreetInsider.com
www.streetinsider.com - May 22 at 3:30 PM
finance.yahoo.com logoAlere Announces Update on Form 10-K and Provides Preliminary Unaudited Financial Results
finance.yahoo.com - May 22 at 3:30 PM
seekingalpha.com logoAlere Q4 top line off 3%; loss/share of $1.41; shares up 2% on resolution accounting errors in South Korea
seekingalpha.com - May 22 at 10:10 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Alere (ALR) Stock?
finance.yahoo.com - May 18 at 12:20 PM
finance.yahoo.com logoGreenlight Capital Quadrupled General Motors Stake in Activist Push
finance.yahoo.com - May 16 at 3:30 PM
americanbankingnews.com logoAlere's (ALR) Neutral Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - May 15 at 1:56 PM
americanbankingnews.com logoAlere Inc (ALR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 15 at 11:22 AM
americanbankingnews.com logoAlere Inc (ALR) Downgraded by Craig Hallum
www.americanbankingnews.com - May 15 at 10:34 AM
finance.yahoo.com logoAlere Inc. Announces Successful Completion of Consent Solicitations for Alere Inc.'s Notes
finance.yahoo.com - May 8 at 8:27 PM
americanbankingnews.com logo Brokerages Anticipate Alere Inc (ALR) Will Post Earnings of $0.34 Per Share
www.americanbankingnews.com - May 5 at 8:22 PM
finance.yahoo.com logoAlere Inc. Announces Modifications of Consent Solicitations for Alere Inc.'s Notes
finance.yahoo.com - May 4 at 3:32 PM
americanbankingnews.com logoPositive News Coverage Very Likely to Impact Alere (ALR) Share Price
www.americanbankingnews.com - May 3 at 10:26 AM
finance.yahoo.com logoAlere Inc. Announces Commencement of Consent Solicitations for Alere Inc.'s Notes
finance.yahoo.com - May 1 at 9:43 AM
americanbankingnews.com logoAlere (ALR) Earning Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 28 at 11:04 AM
americanbankingnews.com logoFavorable News Coverage Likely to Affect Alere (ALR) Share Price
www.americanbankingnews.com - April 25 at 2:31 PM
finance.yahoo.com logoAlere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in Asymptomatic Individuals
finance.yahoo.com - April 25 at 8:43 AM
americanbankingnews.com logoAlere (ALR) Getting Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 10:08 AM
finance.yahoo.com logoAbbott CEO Upbeat Despite Ongoing Merger Headaches
finance.yahoo.com - April 19 at 8:30 PM
americanbankingnews.com logoAlere Inc (ALR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 7:29 PM
rttnews.com logoAlere Inc. (ALR) Jumped After Amended Merger Agreement
www.rttnews.com - April 19 at 3:27 PM
finance.yahoo.com logoAbbott and Alere: It's an M&A Miracle
finance.yahoo.com - April 19 at 3:27 PM
finance.yahoo.com logoAlere Stock Surging on Latest Abbott Agreement
finance.yahoo.com - April 19 at 3:27 PM
finance.yahoo.com logoAlere (ALR) Shows Strength: Stock Adds 15.9% in Session - Yahoo Finance
finance.yahoo.com - April 19 at 7:21 AM
americanbankingnews.com logoAlere Inc (ALR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 12:26 PM
americanbankingnews.com logoAlere (ALR) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 18 at 11:04 AM
americanbankingnews.com logoAlere Inc (ALR) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - April 17 at 4:38 PM
streetinsider.com logoAbbott (ABT) to Acquire Alere (ALR) for $51/Share in Amended Agreement - StreetInsider.com
www.streetinsider.com - April 17 at 3:27 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Incyte, MoneyGram, Alere, OncoMed - Nasdaq
www.nasdaq.com - April 17 at 3:27 PM
finance.yahoo.com logoWill Abbott, Alere Make It To Altar In New Merger Deal?
finance.yahoo.com - April 17 at 3:27 PM
americanbankingnews.com logoAlere Inc (ALR) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - April 17 at 2:16 PM
fool.com logoAlere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories
www.fool.com - April 17 at 1:37 PM
streetinsider.com logoAbbott (ABT) to Acquire Alere (ALR) for $51/Share in Amended Agreement
www.streetinsider.com - April 17 at 7:17 AM
americanbankingnews.com logo Brokerages Expect Alere Inc (ALR) Will Post Quarterly Sales of $586.46 Million
www.americanbankingnews.com - April 16 at 8:02 AM
finance.yahoo.com logo[$$] Abbott, Alere Advance Contentious Merger With Reduced Price
finance.yahoo.com - April 15 at 11:22 AM
americanbankingnews.com logoAlere (ALR) Earning Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 15 at 10:55 AM
americanbankingnews.com logo Brokerages Anticipate Alere Inc (ALR) to Announce $0.45 Earnings Per Share
www.americanbankingnews.com - April 14 at 10:18 PM
nasdaq.com logoAbbott Agrees To Buy Alere At Lower Price
www.nasdaq.com - April 14 at 11:38 AM
marketwatch.com logoAbbott and Alere move forward with merger at lower price
www.marketwatch.com - April 14 at 11:38 AM
finance.yahoo.com logoAbbott and Alere Agree to Play Nice With $5.3 Billion Deal
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logoAbbott and Alere Amend Terms of Merger Agreement
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logoAbbott to slash price it will pay for Alere by nearly 9% to about $5.3 billion
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logoAbbott agrees to buy Alere at lower price from earlier offer
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logoAlere agrees to discounted $5.3B merger with Abbott, ending legal battle
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logo[$$] Abbott, Alere Advance Merger With Reduced Price
finance.yahoo.com - April 14 at 11:38 AM
finance.yahoo.com logoAbbott finalizes discounted deal with Alere, ending legal battle
finance.yahoo.com - April 14 at 11:38 AM
seekingalpha.com logoAbbott Labs to buy Alere for $51/share in amended deal
seekingalpha.com - April 14 at 9:46 AM

Social

Chart

Alere (ALR) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff